The Magazine for Sleep Professionals
Wednesday, September 23, 2026
Patients diagnosed with a temporomandibular disorder (TMD) are at increased risk for obstructive sleep apnea (OSA) compared to people without the disorder, according to a study published in the Journal of Oral and Maxillofacial Surgery (JOMS), the peer-reviewed official journal of the American Association of Oral and Maxillofacial Surgeons (AAOMS). TMD […]
The American Academy of Dental Sleep Medicine (AADSM) announced that 2,500 dentists across the country have achieved AADSM Qualified Dentist status, strengthening patient access to oral appliance therapy (OAT) for obstructive sleep apnea (OSA). OAT offers a comfortable, clinically-proven treatment option for snoring and OSA. The therapy uses a custom-fit oral […]
“Sleep-maxxing” is framed as a commitment to wellness, however clinical evidence suggests this hyper-fixation often functions as a catalyst for sleep impairment. The 2026 American Journal of Lifestyle Medicine review emphasizes that sleep is a process best supported by circadian rhythm alignment and low physiological arousal. When individuals impose rigid […]
Alkermes plc announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and […]
ProSomnus Sleep Technologies (“ProSomnus”) has announced a significant victory in its intellectual property enforcement action, reinforcing the Company’s commitment to protecting the innovations, technologies, and proprietary assets that support advances in sleep medicine. The United States District Court for the Southern District of Florida adopted in full the Magistrate Judge’s Report […]
Haynes Boone represented Cathay Capital and its portfolio company, cpap.com, in the acquisitions of Lofta, LLC from a subsidiary of Accendra Health, Inc, and The CPAPShop from a subsidiary of AdaptHealth Corp. with which a joint venture relationship was also structured, a debt refinancing with Twin Brook Capital Partners, and […]
The ASA has launched a brand new service to the CPAP industry – the CPAP Provider Competency Program. It offers CPAP providers an independent industry-wide education program for CPAP professionals who initiate and maintain patients on CPAP therapy. “This program is a way for CPAP providers to demonstrate their commitment […]
Takeda announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat […]
TAP Sleep Care highlighted clinical evidence on Combination Therapy for CPAP-Resistant Obstructive Sleep Apnea from Martin A. Denbar, DDS, DABDSM, Diplomate of the American Board of Dental Sleep Medicine and Adjunct Assistant Professor in the Department of Internal Medicine at Texas A&M School of Medicine (Texas Dental Sleep Services). The […]
Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. […]
